Notícias e Atividades da Tempest Therapeutics

Veja o organograma con seus 7 executivos principais

Biografias mais buscadas da Tempest Therapeutics

• Matt Angel, Chief Executive Officer
• John Yee, Director
• Drake Richey, Director

Recentes movimentos de executivos em Tempest Therapeutics

• John Yee, ingressou na Companhia como Director  (Notícia publicada em 5 de junho de 2026).
• Drake Richey, ingressou na Companhia como Director  (Notícia publicada em 5 de junho de 2026).
• Mike Raab, Chairman of the Board, deixou a Companhia  (Notícia publicada em 25 de maio de 2026).

Clique aqui para ver outras movimentos em Tempest Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Tempest Therapeutics.

Tempest Therapeutics possui 2.430 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Tempus has announced the acquisition of Personalis  (publicado em 20 de julho de 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Tempest Therapeutics

• Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
• Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference | Tempest Therapeutics
• Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma | Tempest Therapeutics
• Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update | Tempest Therapeutics
• Tempest Extends Limited Duration Stockholder Rights Plan | Tempest Therapeutics
• Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial | Tempest Therapeutics
• Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs | Tempest Therapeutics
• Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
• Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Tempest Therapeutics
• Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Tempest Therapeutics
• View more press releases Close

Redes sociais sobre Tempest Therapeutics

• Tempest Therapeutics na Wikipedia, Google News e Yahoo Finance
• Tempest Therapeutics na LinkedIn, X (Twitter) e YouTube